Bibliography
- Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328:1230–1235.
- Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002;165(9):1217–1239.
- Ruehland WR, Rochford PD, O’Donoghue FJ, et al. The new AASM criteria for scoring hypopneas: impact on the apnea hypopnea index. Sleep. 2009;32(2):150–157.
- US Department of Health and Human Services. Wake up America: a national sleep alert. Bethesda (MD): The Commission; 1993.
- Moon K, Punjabi NM, Aurora RN. Obstructive sleep apnea and type 2 diabetes in older adults. Clin Geriatr Med. 2015;31(1):139–147.
- Abad VA, Guilleminault C. Pharmacological treatment of sleep disorders and its relationship with neuroplasticity. In: Meerlo P, Benca RM, Abel T, editors. Sleep, neuronal plasticity and brain function. Heidelberg: Springer-Verlag; 2015. p. 503–540.
- Konecny T, Kara T, Somers VK. Obstructive sleep apnea and hypertension: an update. Hypertension. 2014;63(2):203–209.
- Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease: a bidirectional relationship. Circulation. 2012;126(12):1495–1510.
- Lipford MC, Flemming KD, Calvin AD, et al. Associations between cardioembolic stroke and obstructive sleep apnea. SLEEP. 2015;38(11):1699–1705.
- Marshall NS, Wong KK, Cullen SR, et al. Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the Busselton Health Study cohort. J Clin Sleep Med. 2014;10(4):355–362.
- Wang X, Ouyang Y, Wang Z, et al. Obstructive sleep apnea and risk of cardiovascular disease and all-cause mortality: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013;169(3):207–214.
- Iftikhar IH, Khan MF, Das A, et al. Meta-analysis: continuous positive airway pressure improves insulin resistance in patients with sleep apnea without diabetes. Ann Am Thorac Soc. 2013;10(2):115–120.
- Resnick HE, Redline S, Shahar E, et al. Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care. 2003;26(3):702–709.
- Foster GD, Sanders MH, Millman R, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care. 2009;32(6):1017–1019.
- Campana L, Eckert DJ, Patel SR, et al. Pathophysiology & genetics of obstructive sleep apnea. Indian J Med Res. 2010;131:176–187.
- Vaessen TJ, Overeem S, Sitskoorn MM. Cognitive complaints in obstructive sleep apnea. Sleep Med Rev. 2015 Feb;19:51–58.
- Ghanim A, Comondore VR, Fleetham J, et al. The economic impact of obstructive sleep apnea. Lung. 2008;186(1):7–12.
- Sassani A 1, Findley LJ, Kryger M, et al. Reducing motor-vehicle collisions, costs, and fatalities by treating obstructive sleep apnea syndrome. Sleep. 2004;27(3):453–458.
- Koo BB, Patel SR, Strohl K, et al. Rapid eye movement-related sleep-disordered breathing: influence of age and gender. Chest. 2008;134:1156–1161.
- Khan A, Sl H, Ej K, et al. Osteoporotic Fractures in Men (MrOS) Study Research Group. Obstructive sleep apnea during rapid eye movement sleep, daytime sleepiness, and quality of life in older men in Osteoporotic Fractures in Men (MrOS) Sleep Study. J Clin Sleep Med. 2013;9:191–198. DOI:10.5664/jcsm.2474.
- McSharry DG, Saboisky JP, Deyoung P, et al. Physiological mechanisms of upper airway hypotonia during REM sleep. Sleep. 2014;37(3):561–569.
- Saboisky JP, Stashuk DW, Hamilton-Wright A, et al. Neurogenic changes in the upper airway of patients with obstructive sleep apnea. Am J Respir Crit Care Med. 2012;185(3):322–329.
- Horner RL 1, Hughes SW, Malhotra A. State-dependent and reflex drives to the upper airway: basic physiology with clinical implications. J Appl Physiol. 1985;116(3):325–336.
- Rao H, Thomas RJ. Complex sleep apnea. Curr Treat Options Neurol. 2013;15(6):677–691.
- Salloum A, Rowley JA, Mateika JH, et al. Increased propensity for central apnea in patients with obstructive sleep apnea: effect of nasal continuous positive airway pressure. Am J Respir Crit Care Med. 2010;181(2):189–193.
- Eckert DJ, White DP, Jordan AS, et al. Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets. Am J Respir Crit Care Med. 2013;188(8):996–1004.
- Gleadhill IC, Schwartz AR, Schubert N, et al. Upper airway collapsibility in snorers and in patients with obstructive hypopnea and apnea. Am Rev Respir Dis. 1991;143(6):1300–1303.
- Younes M, Ostrowski M, Atkar R, et al. Mechanisms of breathing instability in patients with obstructive sleep apnea. J Appl Physiol. 1985;103(6):1929–1941.
- Younes M. Role of respiratory control mechanisms in the pathogenesis of obstructive sleep disorders. J Appl Physiol. 1985;105(5):1389–1405.
- Loewen AH, Ostrowski M, Laprairie J, et al. Response of genioglossus muscle to increasing chemical drive in sleeping obstructive apnea patients. Sleep. 2011;34(8):1061–1073.
- Eckert DJ, Owens RL, Kehlmann GB, et al. Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold. Clin Sci (Lond). 2011;120(12):505–514.
- Younes M. Role of arousals in the pathogenesis of obstructive sleep apnea. Am J Respir Crit Care Med. 2004;169(5):623–633.
- Ohayon MM, Priest RG, Zulley J, et al. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology. 2002;58(12):1826–1833.
- Overeem S, Mignot E, Van Dijk JG, et al. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol. 2001;18(2):78–105.
- Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369(9560):499–511.
- Hagan JJ, Leslie RA, Patel S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A. 1999;96(19):10911–10916.
- Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355(9197):39–40.
- Mignot E, Lammers GJ, Ripley B, et al The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553–1562.
- Liblau RS, Vassalli A, Seifinejad A, et al. Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy. Lancet Neurol. 2015;14(3):318–328.
- International Classification of Sleep Disorders. 3rd ed. Darien (IL): American Academy of Sleep Medicine; 2014.
- Wozniak DR, Quinnell TG. Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nat Sci Sleep. 2015;7:51–61.
- Weaver TE, Maislin G, Dinges DF, et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep. 2007;30(6):711–719.
- Weaver TE, Calik MW, Farabi SS, et al. Innovative treatments for adults with obstructive sleep apnea. Nat Sci Sleep. 2014;6:137–147.
- Roselaar SE, Langdon N, Lock CB, et al. Selegiline in narcolepsy. Sleep. 1987;10(5):491–495.
- Mignot E. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. 2012;9(4):739–752.
- Wozniak DR, Quinnell TG. Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nat Sci Sleep. 2015;7:51–61.
- Black JE, Hull SG, Tiller J, et al. The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. J Clin Sleep Med. 2010;6:458–466.
- Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. Jama. 2009;301(11):1148–1154.
- Spencer TJ, Madras BK, Bonab AA, et al. A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using [¹¹C]altropane and [¹¹C]raclopride. Biol Psychiatry. 2010;68(10):964–970. DOI:10.1016/j.biopsych.2010.08.026.
- Niederhofer H. Atomoxetine also effective in patients suffering from narcolepsy? Sleep. 2005;28(9):1189.
- Morgenthaler TI, Kapur VK, Brown T, et al. Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705–1711.
- Mignot E, Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep. 2005;28(6):754–763.
- Broderick M, Guilleminault C. Rebound cataplexy after withdrawal from antidepressants. Sleep Med. 2009;10(4):403–404.
- Morgenthaler T, Kapur VK, Brown T, et al., et. al Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;3012:1705–1711.
- Koek W, France CP. Cataleptic effects of gamma-hydroxybutyrate (GHB) and baclofen in mice: mediation by GABA(B) receptors, but differential enhancement by N-methyl-d-aspartate (NMDA) receptor antagonists. Psychopharmacology (Berl). 2008;199(2):191–198.
- Van Amsterdam JG, Brunt TM, McMaster MT, et al. Possible long-term effects of γ-hydroxybutyric acid (GHB) due to neurotoxicity and overdose. Neurosci Biobehav Rev. 2012;36:1217–1227.
- Mamelak M, Swick T, Emsellem H, et al. A 12-week open-label, multicenter study evaluating the safety and patient-reported efficacy of sodium oxybate in patients with narcolepsy and cataplexy. Sleep Med. 2015;16(1):52–58.
- Feldman NT. Xyrem safety: the debate continues. Sleep Med. 2009;10(4):405–406.
- Poli F, Ricotta L, Vandi S, et al. Catathrenia under sodium oxybate in narcolepsy with cataplexy. Sleep Breath. 2012;16(2):427–434.
- Mason M, Cates CJ, Smith I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev.2015.(7):Art. No.: CD011090. DOI:10.1002/14651858.CD011090.pub2.
- Mason M, Welsh EJ, Smith I. Drug therapy for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. 2013;5:CD003002.
- Veasey SC, Guilleminault C, Strohl KP, et al Medical Therapy for obstructive sleep apnea: a review by the medical therapy for obstructive sleep apnea task force of the standards of practice committee of the american academy of sleep medicine. Sleep. 2006;29:1036–1044.
- Dayat E, Serpero L, Kheirandish-Gozal L, et al Leukotriene pathways and in vitro adenotonsillar cell proliferation in children with obstructive sleep apnea. Chest. 2009;135:1142–1149.
- Guilleminault C, Philip P. Tiredness and somnolence despite initial treatment of obstructive sleep apnea syndrome (what to do when an OSAS patient stays hypersomnolent despite treatment). Sleep. 1996;19(9 Suppl):S117–22.
- Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure–treated obstructive sleep apnea/hypopnea syndrome. Sleep. 2005;28:464–471.
- Roth T, White D, Schmidt-Nowara W, et al Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP- adherent adults. Clin Ther. 2006;28:689–706.
- Grace KP, Hughes SW, Shahabi S, et al. K+ channel modulation causes genioglossus inhibition in REM sleep and is a strategy for reactivation. Respir Physiol Neurobiol. 2013;188:277–288. DOI:10.1016/j.resp.2013.07.011.
- Sukys-Claudino L, Moraes W, Guilleminault C, et al. Beneficial effect of donepezil on obstructive sleep apnea: a double-blind, placebo-controlled clinical trial. Sleep Med. 2012;13:290–296.
- Hedner J, Kraiczi H, Peker Y. Reduction of sleep-disordered breathing after physostigmine. Am J Respir Crit Care Med. 2003;168:1246–1251.
- Calik MW, Radulovacki M, Carley DW. Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat. Respir Physiol Neurobiol. 2014;190:20–24.
- Burgess KR. New insights from the measurement of loop gain in obstructive sleep apnoea. J Physiol. 2012;590(Pt 8):1781–1782.
- Inoue Y, Takata K, Sakamoto I, et al Clinical efficacy and indication of acetazolamide treatment on sleep apnea syndrome. Psychiatry Clin Neurosci. 1999;53:321–322.
- Edwards BA, Connolly JG, Campana LM, et al. Acetazolamide attenuates the ventilatory response to arousal in patients with obstructive sleep apnea. Sleep. 2013;36(2):281–285.
- John J, Wu MF, Siegel JM. Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online. 2000;3(1):23–28.
- Lee MG, Hassani OK, Jones BE. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci. 2005;25(28):6716–6720.
- Fujiki N, Yoshida Y, Ripley B, et al. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep. 2003;26(8):953–959.
- Broderick M, Guilleminault C. Emerging treatments for narcolepsy. In: Goswani M, Pandi-Perumal SR, Thorpy M, editors. Narcolepsy: a clinical guide. New York (NY): Humana Press, 2010. pp. 301–311.
- Mignot E, Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep. 2005;28(6):754–763.
- Lin JS, Sergeeva OA, Haas HL. Histamine H3 receptors and sleep-wake regulation. J Pharmacol Exp Ther. 2011;336:17–23.
- Heuer H, Schäfer MK, O’Donnell D, et al. Expression of thyrotropin-releasing hormone receptor 2 (TRH-R2) in the central nervous system of rats. J Comp Neurol. 2000;428(2):319–336.
- Riehl J, Honda K, Kwan M, et al. Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology. 2000;23(1):34–45.
- Nishino S, Arrigoni J, Shelton J, et al. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci. 1997;17(16):6401–6408.
- Prasad B, Radulovacki MG, Carley DW. Proof of concept trial of dronabinol in obstructive sleep apnea. Front Psychiatry. 2013;4:1.
- Farabi SS, Prasad B, Quinn L, et al. Impact of dronabinol on quantitative electroencephalogram (qEEG) measures of sleep in obstructive sleep apnea syndrome. J Clin Sleep Med. 2014;10(1):49–56.
- [cited 2015 Jan 25]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01755091?term=UIC&rank=46.
- [cited 2015 Jan 25]. Available from: http://www.cortexpharm.com/product/index.html.
- [cited Jan 27, 2014]. Available from: https://clinicaltrials.gov/ct2/show/NCT02220803.
- [ cited 2015 Jan 27]. Available from: http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=4983.
- [cited 2015 Jan 27]. http://www.applegate.co.uk/b2b-news/articles/alium-medical-announces-exclusive-distribution-rights-narcolepsy-innovative-product-wakix-63670.html.
- Ligneau X, Perrin D, Landais L, et al. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. J Pharmacol Exp Ther. 2007;320(1):365–375.
- Schwartz JC1. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163(4):713–721.
- Uguen M, Perrin D, Belliard S, et al. Preclinical evaluation of the abuse potential of pitolisant, a histamine H3 receptor inverse agonist/antagonist compared with modafinil. Br J Pharmacol. 2013;169(3):632–644.
- Zhang DD, Sisignano M, Schuh CD, et al. Overdose of the histamine H3 inverse agonist pitolisant increases thermal pain thresholds. Inflamm Res. 2012;61(11):1283–1291.
- Dauvilliers Y, Bassetti C, Lammers GJ, et al. HARMONY I study group. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068–1075.
- https://clinicaltrials.gov/ct2/show/NCT01399606?term=pitolisant&rank=2
- [cited Jan 27, 2015]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01789398?term=NCT01789398+%28Harmony+IV%29&rank=1.
- Inocente C, Arnulf I, Bastuji H, et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol. 2012;35(2):55–60.
- [cited 2015 Jan 27]. Available from: http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=520672.
- [cited 2015 Jan 27]. https://clinicaltrials.gov/ct2/show/record/NCT00424931?term=JNJ-17216498&rank=1.
- [cited 2015 Jan 27]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT00366080?term=GSK+189254&rank=2.
- [ cited 2015 Jan 27]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01681121.
- [cited 2015 Jan 27]. Available from: http://aerialbio.com/2013/06/05/adx-no5-results-presented-at-sleep-2013-meeting/.
- [cited Jan 27, 2015]. Available from: http://www.jazzpharma.com/rd-or-development/.
- [cited 2015 Jan 27]. Available from: http://www.jazzpharma.com/rd-or-development/.
- [cited 2015 Jul 28]. Available from: http://investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-newsArticle&ID=2045672.
- [cited 2015 Jan 26]. Available from: http://www.drugs.com/pro/acetazolamide-tablets.html.